Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Page 27 Page 28 Page 29 Page 30 Page 31 Page 32A N D C H A I R M A N and the countless individuals who need our help. Simply put, our goal is to bring the most advanced technologies in the most efficient way possible to the most people in need. As an organization, AdvaMed is better positioned today than at any time in its history to continue to advance our goal, with an expanding membership that stands as testament to the extraordinary value AdvaMed provides. Looking back on 2016, the Association marked key milestones that yielded important benefits to AdvaMed members and the patients they serve. These include: •  Implementation of a two-year suspension of the medical device tax, saving our industry nearly $2 billion annually, and ongoing messaging on the benefits of suspension to drive innovation, which has advanced our efforts for permanent repeal; •  Completion of a pro-innovation FDA user fee reauthorization agreement, committing the agency to continued improvements in the efficiency, predictability and transparency of review processes; •  Enactment of 21st Century Cures legislation with key regulatory reforms proposed by AdvaMed, including a breakthrough pathway provision to improve use of FDA’s Expedited Access program; •  Progress on AdvaMed’s value framework initiative, aimed at helping members demonstrate the value of technologies in a consistent and effective fashion, to support positive coverage and payment decisions; •  Launch of AdvaMed Digital to support members in the burgeoning digital health space, and debut of the AdvaMed Purchasing Group to help members save on commonly used goods and services; •  Ongoing AdvaMedDx advocacy for diagnostic regulatory reforms, effective implementation of laboratory test payment reforms and recognition of diagnostics in key public health initiatives; •  Continued advocacy through AdvaMed Accel for legislation – including revisions to the tax code – and regulatory, reimbursement and compliance initiatives that promote investment in small firms, alongside strategic partnerships that support the medtech innovation ecosystem; •  Achievement of key international objectives, such as implementation of a China-specific code of ethics, China’s commitment to improve its regulatory system and develop a harmonized system of unique device identifiers, and staving off price controls in key geographies; and •  Creation of our largest and most successful MedTech Conference ever in Minneapolis. To build on our successes over the past year, AdvaMed has an exciting and ambitious agenda ahead. We recognize the challenges before us. But for us to succeed will require the engagement of all our members – from the largest multinationals to the smallest innovators – and all the creativity and ingenuity that is the hallmark of our industry. We hope that you will join us as an active participant, for the benefit of the industry, for the good of your company and for the sake of so many patients in need. VINCENT A. FORLENZA Chairman, President and Chief Executive Officer BD Chairman, AdvaMed SCOTT WHITAKER President and Chief Executive Officer AdvaMed 3